Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel- sar Early choroidal melanoma investor and analyst virtual event planned for December 8, 2026 Expected cash runway into 1H 2029 BOSTON, MA – November 9, 2026 – Aura Biosciences, Inc. (NASDAQ: AURA) ("Aura" ...